Press Room

Press Clipping / Sep 09, 2019

The Mark of a Great Company

BITCI News, September 09, 2019

The Mark of a Great Company | Hovione

Pictured above were Gillian Chamberlain, BT with Maarten Schuuruman, MD, HEINEKEN Ireland, Bernard Sheridan, Corporate Affairs Director, Central Bank of Ireland and Paul Downing, General Manager, Hovione.

 

The 2019 Edelman Trust Barometer recently revealed that 75% of Irish people expect CEOs to take the lead on social change issues. Business in the Community Ireland has developed the Business Working Responsibly mark, the only independently audited standard for CSR and Sustainability in Ireland. The Mark can put your CEO and company at the forefront of social change, pioneering best practices in human rights and other social areas, and enabling others to follow suit. To date, 33 of the largest organisations operating in Ireland are certified to the Mark, and testimonials from their CEOs speak to the many benefits associated with certification.

“We want to attract the best talent and having the Mark is a clear demonstration of our responsible business practices and signals to existing and potential staff that we are serious about our corporate social responsibility” – Clive Bellows, Country Head, Northern Trust

 “For our businesses in Ireland, being certified with the Business Working Responsibly Mark helps to convey to employees, customers, local communities and stakeholders that we are fully committed to managing our operations in a socially responsible and sustainable manner “- Oliver Mahon, Senior Vice President – CRH Europe North

So what are some of the benefits of achieving Mark certification?

1. Employee Engagement and Retention

In the last decade the workforce has changed, and with it the culture of the workplace. Together Millennials and Gen Zs make up more than half the world’s population and account for most of the global workforce[1]. This new generation of workers places a much larger focus on social and environmental responsibility. Policies around diversity and inclusion, flexible working and rewards and recognition are being put under the spotlight, as the new workforce wants to work for companies that offer them a socially responsible purpose, without “sacrificing the flexibility to be who they are at work and live a fulfilling life outside of it”[2]. This flexibility doesn’t just mean flexible work hours or locations, but a more inclusive workplace and fair and transparent opportunities for progression.

The Mark takes a focus across all of these workplace indicators and assesses company policies, practices and performance in achieving objectives. Achieving the independently verified certification can enhance your employer brand and help attract and retain employees.

[1] https://www2.deloitte.com/global/en/pages/about-deloitte/articles/mille…

[2] https://www2.deloitte.com/content/dam/Deloitte/us/Documents/about-deloi…

 

2. Customer Relationships

Not only is flexibility in the workplace becoming an essential part of any recruitment package, but so is the impact that a business has on both society and the environment. Research shows that millennials are the most socially conscious generation since the 1960’s[1] and climate change is topping their list of concerns[2] . They are expressing these values both in the demands they make as employees and in the demands they made as consumers. Present day consumers are making socially conscious choices and choosing products that meet their ethical requirements. According to the recent Deloitte Millenial Survey[3], “42% of millennials have begun or deepened a business relationship because they perceive a company’s products or services to have a positive impact on society and/or the environment. Further, 37 percent said they have stopped or lessened a business relationship because of the company’s ethical behaviour.”

The Mark looks at the value chain of companies, and assesses whether their products and service are both socially and environmentally responsible. The certification process also examines the company’s environmental footprint, including waste reduction and carbon emissions amongst much more.

 

3. CEOs as Leaders of Change

Mark certification gives you access to Leaders’ Group on Sustainability, a collaboration between the CEOs of some of Ireland’s largest organisations, addressing pressing social, economic and environmental challenges. This year the Leader’s Group has produced the Low Carbon Pledge, with 49 of Ireland’s largest companies committing to lowering their scope 1&2 emissions by 50% by 2030, and the Social Inclusion Blueprint, a practical guide to create inclusive workplaces and reduce inequality in Ireland.

What does the Mark certification involve?

The Mark can help your company to raise your brand’s CSR profile and better recruit, retain, and engage your employees. Audited by the National Standards Authority of Ireland (NSAI), and based on ISO 26000, The Mark will assess your responsible and sustainable business practices and provide your organisation with an assessment of how well positioned it is to address CSR risks and opportunities in the current business environment. The assessment addresses policies, practices and company performance across five pillars (Governance, Marketplace, Workplace, Environment, and Community which encompass 22 indicators, including Employee Engagement, Responsible Products and Services, Carbon Management and Climate Change Adaptation, and Community Engagement.

Achieving the Mark Certification provides independent verification that will enhance your employer brand, help attract and retain employees, support your corporate responsibility and sustainability credentials and support your organisation in leveraging investment potential.

 

Read article

 

Also in the Press Room

See All

The latest from CDMOs, CMOs, and suppliers featuring Thermo Fisher Scientific, Lonza, SK pharmteco/Lotte Biologics, Hovione, Sai Life Sciences, BioCina, Alcami, Piramal Pharma/IntoCell and Roquette. Formulation Development/Drug Product Manufacturing: Hovione Completes Initial $100-M Investment Cycle in US Operations Hovione, a CDMO of drug substances and drug products, has completed an initial $100-million investment cycle at its site in East Windsor, New Jersey, as part of a strategy to increase its US operations and enhance its integrated drug-substance, drug-product intermediate, and drug-product capabilities. Upon completion, the site will cover more than 200,000 square feet.   The initial expansion phase includes a 31,000-square-foot building that will house two size-3 spray dryers (PSD-3) designed for production of amorphous solid dispersions (ASDs). This investment more than doubles Hovione’s spray-drying capacity in the US by expanding capabilities for ASD development and commercial manufacturing. Construction is underway at the New Jersey site, with GMP operations planned to start in the second quarter of 2026.  As part of this expansion, Hovione has also acquired additional adjacent land to enable future growth at the East Windsor site. The 125,000-square-foot greenfield will support large-scale production, including continuous and batch tableting capacity, and introduce the latest pharmaceutical technologies and digital innovation with enhanced quality control and R&D capabilities.    Read the full article at DCATvci.org  

Press Clipping

Supplier News: Thermo Fisher, Lonza, SK pharmteco, Hovione & More

Oct 30, 2025

Today marks the start of CPhI Frankfurt, a huge trade show in Germany focused on the supply of pharmaceutical ingredients and other services to the drug industry. C&EN editor in chief Nick Perkins, life sciences editor Laura Howes, and reporter Aayushi Pratap are all there to meet drug outsourcing executives and take the pulse of the sector. In advance of CPhI, Cambrex and Wilmington PharmaTech both just announced big investments in US plants that make active pharmaceutical ingredients. And the Portuguese pharmaceutical services firm Hovione says it has completed a $100 million investment in New Jersey (story below). (...) Hovione invests in spray-drying in New Jersey The pharmaceutical services firm Hovione says it has spent $100 million to expand its operation in East Windsor, New Jersey. The facility spray-dries drug ingredients to create amorphous solid dispersions, which improve solubility and bioavailability. The Portuguese company says the new spray dryers will begin operating in the second quarter of 2026. The New Jersey facility opened in 2002, making Hovione one of the longest-established European pharmaceutical services firms in the US, CEO Jean-Luc Herbeaux says in a press release. Hovione says it has purchased land adjacent to the East Windsor site on which it can add new facilities for services such as spray-drying and drug tableting. Hovione is also investing at its sites in Ireland and Portugal. —Michael McCoy   Read the full article at CEN.acs.org  

Press Clipping

Oct. 28 Business Watch: More plants closing in Europe, Novartis to pay $12 billion for biotech firm

Oct 28, 2025

Developing drugs with poor water solubility remains a major challenge for pharmaceutical manufacturers, because solubility impacts bioavailability and effective drug delivery. The vast majority of small molecule drug candidates have low water solubility. For more than two decades, the most successful particle engineering technology to improve drug solubility and bioavailability has been spray drying with an amorphous solid dispersion (ASD) platform. Spray drying improves the solubility of oral drugs, inhalable particles, and excipients, and increases the stability of heat-sensitive drug products. Hovione, recognized globally for its industry-leading spray drying capabilities, has recently completed a $100 million investment cycle to enhance its operations in New Jersey. This initiative has successfully doubled Hovione’s spray-drying capacity in the US, strengthening its position in the industry. Hovione’s Expanded U.S. Site in East Windsor, NJ  The first phase of the expansion in East Windsor, NJ, delivers a new 31,000 square foot facility and houses two size-3 spray dryers (PSD-3). This additional capacity allows Hovione to meet increasing customer demand for ASD development and good manufacturing practice (GMP) commercial production. GMP operations are scheduled to commence in the second quarter of 2026.  Hovione has also acquired 15 acres of neighboring land, strategically positioning itself for future growth and evolving customer needs for U.S. manufacturing. The newly acquired greenfield site will provide future support for PSD-4–scale commercial production as well as continuous and batch tableting production. It will also be a hub for centralized logistics, enhanced quality control laboratories, and next-generation research and development facilities.  A Global CDMO with a Growing U.S. Footprint  Hovione has operated in New Jersey for more than two decades, establishing itself with a strong U.S. presence for the production of drug substances, intermediates, and finished drug products. A continued emphasis on an integrated service offering, including spray drying, supports delivering innovative medicines to patients more quickly.  The expansion of the East Windsor site addresses the rising demand for U.S. manufacturing and is an integral part of the company's ongoing global growth strategy, with facilities in Portugal, Ireland, and Macau. The company continues to bolster a cohesive network for drug development and commercial manufacturing unified by a corporate quality system and governance framework.  The integrated offering enhances development speed and eases technology transfers by unifying the team's technical skills, proprietary technologies, and digital platforms to efficiently produce drug substance to drug products at a single-site, through Hovione’s “one site, one partner” vision. Furthermore, Hovione’s strategic partnership model offers customers exclusive access to advanced technologies and resources while aiding in the optimization of their development programs and ensuring sustained value creation.  End-to-End Spray Drying and Particle Engineering: From Grams to Tons Hovione is a global leader in spray drying and particle engineering. Services include solubility enhancement and controlled-modified release via development and production of ASDs of both small and large molecules, supporting various modalities. ASD-HIPROS, Hovione’s proprietary spray drying screening platform, identifies optimal formulations that offer optimal performance and stability. By increasing production volume in the US, Hovione will meet customer demand for spray drying services:  Development services in the laboratory (1 g – 1 kg batches)  Pilot scale production (0.5 – 25 kg batches)  Small-scale production (5 – 200 kg batches)  Large-scale commercial manufacturing (50 – 400 kg batches) A Commitment to Sustainability  Hovione’s core values include a commitment to sustainability at all facilities. This commitment is reflected in a business strategy that focuses on improving the communities where the company operates. Hovione’s sustainability policy and strategy align with the UN Sustainable Development Goals and include adherence to science-based targets in line with the Paris Agreement to address climate change. Meeting these goals has required a dedication to process intensification and ensuring sustainability of manufacturing processes. This has been possible through strategic planning and commitments from senior management to ensure sustainability is addressed throughout the drug development life cycle.  Partner with a Technology-Leading CDMO for U.S. Manufacturing   As demand for poorly water-soluble drug formulations continues to rise in the U.S., expanding spray drying throughput is essential to meet the need for innovative therapeutics. With proven leadership in spray drying to manufacture ASDs, Hovione is able to support pharmaceutical companies by solving their solubility challenges efficiently and reliably.  Partnering with a CDMO that combines global leadership, advanced technologies, and the necessary manufacturing capacity in the U.S., drug developers can expedite time to market, ensure quality, and deliver innovative medicines to patients faster.  If your company is seeking access to the latest spray-drying capabilities, expanded U.S. manufacturing capacity, and an accelerated path to regulatory filing and commercialization, contact our team today.     

News

Hovione is Expanding Spray Drying Capacity for U.S. Drug Manufacturing

Oct 27, 2025